Monash IVF Group Ltd (ASX: MVF) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Monash IVF Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Monash IVF Group Ltd (ASX: MVF)
Latest News
⏸️ Investing
Why I think Monash IVF Group Ltd shares look a buy
⏸️ Investing
Why these 5 ASX shares have CRASHED lower today
⏸️ Investing
Why Virtus Health Ltd shares are being SLAMMED on its trading update
⏸️ Investing
3 under-the-radar high-yielding dividend shares to buy today
⏸️ Investing
These 3 IVF providers could give your portfolio a bump in growth
⏸️ Investing
3 healthcare shares that I think could be bargain buys today
⏸️ Investing
3 ASX bargains on my Christmas shopping list
⏸️ Investing
3 high-yield dividend shares for retirees in 2017
⏸️ Investing
Is Virtus Health Ltd a buy after its latest overseas acquisition?
⏸️ Investing
3 healthcare shares I think are in the buy zone right now
⏸️ Investing
A True Trump Trade to make your portfolio great again
⏸️ Investing
Are these shares the biggest bargains on the S&P/ASX 200?
Frequently Asked Questions
-
Yes, Monash IVF Group has historically paid two fully franked shareholder dividends a year.
-
Monash IVF Group generally pays its shareholder dividends in April and October.
-
Monash IVF Group listed on the ASX on 26 June 2014.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
05 Sep 2024 | $0.0250 | 100.00% | Final | 11 Oct 2024 |
07 Mar 2024 | $0.0250 | 100.00% | Interim | 05 Apr 2024 |
07 Sep 2023 | $0.0220 | 100.00% | Final | 11 Oct 2023 |
08 Mar 2023 | $0.0220 | 100.00% | Interim | 06 Apr 2023 |
08 Sep 2022 | $0.0220 | 100.00% | Final | 07 Oct 2022 |
07 Mar 2022 | $0.0220 | 100.00% | Interim | 04 Apr 2022 |
09 Sep 2021 | $0.0210 | 100.00% | Final | 08 Oct 2021 |
09 Mar 2021 | $0.0210 | 100.00% | Interim | 07 Apr 2021 |
05 Mar 2020 | $0.0210 | 100.00% | Interim | 02 Oct 2020 |
05 Sep 2019 | $0.0300 | 100.00% | Final | 11 Oct 2019 |
06 Sep 2018 | $0.0260 | 100.00% | Final | 12 Oct 2018 |
08 Mar 2018 | $0.0340 | 100.00% | Interim | 06 Apr 2018 |
06 Sep 2017 | $0.0000 | 100.00% | Final | 13 Oct 2017 |
02 Mar 2017 | $0.0430 | 100.00% | Interim | 07 Apr 2017 |
06 Sep 2016 | $0.0450 | 100.00% | Final | 14 Oct 2016 |
08 Mar 2016 | $0.0400 | 100.00% | Interim | 08 Apr 2016 |
MVF ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Monash IVF Group Ltd
Monash IVF Group Ltd (ASX: MVF) is a specialist assisted reproductive services provider. The company offers fertility treatments and specialist diagnostic obstetric and gynaecological ultrasound services. Monash is among the leading providers of assisted reproductive services in Australia and Malaysia. It also has a cooperative agreement with a hospital in China.
MVF Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Dec 2024 | $1.24 | $0.02 | 1.64% | 485,936 | $1.22 | $1.24 | $1.21 |
19 Dec 2024 | $1.22 | $-0.02 | -1.62% | 321,736 | $1.24 | $1.24 | $1.21 |
18 Dec 2024 | $1.24 | $-0.01 | -0.80% | 333,209 | $1.26 | $1.26 | $1.23 |
17 Dec 2024 | $1.25 | $0.02 | 1.63% | 272,207 | $1.24 | $1.26 | $1.23 |
16 Dec 2024 | $1.23 | $-0.02 | -1.60% | 911,094 | $1.25 | $1.26 | $1.23 |
13 Dec 2024 | $1.25 | $0.00 | 0.00% | 609,225 | $1.26 | $1.26 | $1.24 |
12 Dec 2024 | $1.25 | $0.02 | 1.63% | 294,782 | $1.24 | $1.26 | $1.23 |
11 Dec 2024 | $1.23 | $-0.03 | -2.39% | 1,024,415 | $1.26 | $1.26 | $1.23 |
10 Dec 2024 | $1.26 | $-0.01 | -0.79% | 613,454 | $1.29 | $1.29 | $1.25 |
09 Dec 2024 | $1.26 | $0.02 | 1.62% | 849,712 | $1.25 | $1.28 | $1.24 |
06 Dec 2024 | $1.24 | $-0.01 | -0.80% | 248,872 | $1.25 | $1.26 | $1.23 |
05 Dec 2024 | $1.25 | $0.02 | 1.63% | 389,962 | $1.25 | $1.25 | $1.23 |
04 Dec 2024 | $1.23 | $-0.01 | -0.81% | 978,202 | $1.25 | $1.25 | $1.22 |
03 Dec 2024 | $1.24 | $0.03 | 2.48% | 548,464 | $1.22 | $1.25 | $1.22 |
02 Dec 2024 | $1.21 | $0.01 | 0.83% | 311,446 | $1.22 | $1.22 | $1.20 |
29 Nov 2024 | $1.20 | $0.00 | 0.00% | 348,238 | $1.20 | $1.21 | $1.19 |
28 Nov 2024 | $1.20 | $-0.02 | -1.65% | 439,881 | $1.22 | $1.25 | $1.20 |
27 Nov 2024 | $1.22 | $0.05 | 4.27% | 883,774 | $1.17 | $1.23 | $1.16 |
26 Nov 2024 | $1.17 | $0.04 | 3.54% | 776,549 | $1.14 | $1.17 | $1.13 |
25 Nov 2024 | $1.13 | $0.00 | 0.00% | 353,718 | $1.14 | $1.14 | $1.13 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
03 Dec 2024 | Michael Knaap | Issued | 614,447 | $761,914 |
Issue of securities. 1,664,479 Rights
|
31 Oct 2024 | Josef Czyzewski | Transfer | 19,101 | $22,443 |
Off-market transfer. Assuming off market transfer of shares
|
31 Oct 2024 | Josef Czyzewski | Transfer | 19,101 | $22,443 |
Off-market transfer. Assuming off market transfer of shares
|
16 Sep 2024 | Catherine (Cathy) Aston | Buy | 2,000 | $2,422 |
On-market trade.
|
16 Sep 2024 | Catherine (Cathy) Aston | Buy | 75,000 | $90,847 |
On-market trade.
|
13 Sep 2024 | Michael Knaap | Exercise | 466,166 | $550,075 |
Conversion of securities. 1,050,032 Rights
|
13 Sep 2024 | Michael Knaap | Buy | 157,317 | $185,634 |
Conversion of securities.
|
17 Apr 2024 | Michael Knaap | Exercise | 501,629 | $722,345 |
Conversion of securities. 1,516,198 Rights
|
17 Apr 2024 | Michael Knaap | Buy | 577,325 | $831,348 |
Conversion of securities.
|
17 Apr 2024 | Michael Knaap | Exercise | 501,629 | $722,345 |
Conversion of securities. 1,516,198 Rights
|
17 Apr 2024 | Michael Knaap | Issued | 501,629 | $722,345 |
Conversion of securities.
|
17 Apr 2024 | Michael Knaap | Issued | 75,696 | $109,002 |
Dividend Reinvestment Plan (DRP).
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Zita Peach | Non-Executive Director | Oct 2016 |
Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for industry players such as CSL Limited, Fresenius Kabi and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita is currently a Non-Executive Director of three private equity owned companies, Icon Group Pty Ltd, VetPartners Pty Ltd and Nucleus Network Pty Ltd. Zita is also the Chair of the Olivia Newton John Cancer Research Institute. Former directorships (last 3 years): Starpharma Holdings Limited.
|
Mr Richard Hugh Davis | Non-Executive ChairmanNon-Executive Director | Jun 2014 |
Mr. Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is member of risk committee.
|
Mr Neil John Broekhuizen | Non-Executive Director | Jun 2014 |
Mr. Broekhuizen is the Joint Chief Executive Officer of Ironbridge. Neil has over 30 years' experience in the finance industry including 28 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. Former directorships (last 3 years): Bravura Solutions Limited. He is member of Risk Committee.
|
Mr Michael Damian Knaap | Chief Executive OfficerManaging Director | Sep 2015 |
Mr Knaap has 30 years of experience in executive positions with a financial, operational, strategic and leadership background in Healthcare and FMCG industries. Prior to joining MVF Group, Michael was with Patties Foods Limited where he held a number of executive positions over six years, including the role of Chief Financial Officer and Company Secretary.
|
Dr Richard Charles Henshaw | Executive Director | Apr 2014 |
Dr Henshaw MD FRANZCOG FRCOG has practiced in the field of reproductive medicine since 1995. Richard works as a Fertility Specialist for the Group. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
|
Ms Catherine Jane West | Non-Executive Director | Sep 2020 |
Ms West has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the United Kingdom and Europe. Catherine is Non Executive Director of Peter Warren Automotive Group. In addition, she is Chair of the National Institute of Dramatic Art (NIDA), a Director of the NIDA Foundation and Chair of the Board of Governors of Wenona School. Catherine was also until recently, a Director of the Sydney Breast Cancer Foundation Limited until her resignation on 30th June 2024. She formerly held directorship with Endeavour Group.
|
Ms Catherine (Cathy) Ann Aston | Non-Executive Director | Feb 2024 |
Ms. Catherine Aston is an experienced Non-Executive Director / Chair of listed and unlisted entities covering technology, financial services, marketing services, health and government sectors across Australia and Asia. Catherine has a commercial background with executive roles in finance, marketing and strategy, including as CFO for Telstra International and Chief Executive Officer of a mobiles joint venture in Sri Lanka. Catherine is currently a Non Executive Director of Macquarie Investment Management Ltd (Chair of the Audit, Risk and Compliance committee), IVE Group Ltd (Chair of the Audit and Risk Committee) and IMB Bank Ltd (Chair). Catherine's advisory roles have included work with the NSW State Government and serving as an advisory board member of Avanseus Pty Ltd, a Singapore based AI business. Former directorships (last 3 years): Virtus Health Ltd, Integrated Research Ltd, Over the Wire Ltd.
|
Mr Malik Jainudeen | Chief Financial OfficerCompany Secretary | Apr 2019 |
-
|
Jan Lagerwij | Asia Managing Director |
-
|
|
Malik Jainudeen | Chief Financial OfficerCompany Secretary |
-
|
|
Tedd Fuell | Chief Governance & Risk Officer |
-
|
|
Thierry Panthier | Chief Information Officer |
-
|
|
Fiona Allen | Chief Marketing Officer |
-
|
|
Hamish Hamilton | Chief Operating Officer |
-
|
|
Peggy North | Chief People & Culture Officer |
-
|
|
Deirdre Zander Fox | Chief Scientific Officer |
-
|
|
Sloane Karlson | General Manager Projects |
-
|
|
Prof Luk Rombauts | Group Medical Director |
-
|
|
Sarah Bollom | Regional Donor & Surrogacy Manager |
-
|
|
Monique Teodoro | Regional Manager Day Surgeries |
-
|
|
Rebecca Redden | Regional Manager for Ultrasound SA/NT and Genetics |
-
|
|
Claire Ellem | Regional Manager QLD |
-
|
|
Nicolette Curtis | Regional Manager VIC & NSW |
-
|
|
Kate Robertson | Regional Manager WA |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 82,222,688 | 21.10% |
Citicorp Nominees Pty Limited | 67,647,801 | 17.36% |
J P Morgan Nominees Australia Pty Limited | 64,131,568 | 16.46% |
Argo Investments Limited | 20,292,940 | 5.21% |
Washington H Soul Pattison And Company Limited | 18,675,000 | 4.79% |
Bnp Paribas Nominees Pty Ltd | 9,120,255 | 2.34% |
Palm Beach Nominees Pty Ltd | 7,813,727 | 2.01% |
Ubs Nominees Pty Ltd | 6,645,317 | 1.71% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 3,648,216 | 0.94% |
Neweconomy Com Au Nominees Pty Limited | 3,473,430 | 0.89% |
National Nominees Limited | 3,376,384 | 0.87% |
Pacific Custodians Pty Limted | 2,579,603 | 0.66% |
Ippoliti Pty Ltd | 2,245,945 | 0.58% |
Mr Prashant Nadkarni | 2,011,336 | 0.52% |
Vollenhoven Investments Pty Ltd | 1,461,484 | 0.38% |
Mclachlan Future Fund Pty Ltd | 1,447,787 | 0.37% |
Ong Administration Pty Ltd | 1,300,000 | 0.33% |
BNP Paribas Nominees Pty Ltd i | 1,201,906 | 0.31% |
Dalyne Pty Ltd | 1,172,933 | 0.30% |
Citicorp Nominees Pty Limited i | 1,170,000 | 0.30% |